Cartesian Therapeutics, Inc. (RNAC) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 4.15
30Y Low4.2·High4.2
P/FCF
N/A
—
5yr avg: N/A
30Y Low7.5·High7.5
P/B Ratio
↓
N/A
—
5yr avg: 7.63
30Y Low1.5·High13.8
ROE
↑
N/A
—
5yr avg: -538.5%
30Y Low-282%·High61%
Debt/EBITDA
N/A
—
5yr avg: 2.29
30Y Low2.3·High2.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RNAC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cartesian Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $216M | $187M | $424M | $107M | $137M | $311M | $256M | $90M | $50M | $167M | $150M |
| Enterprise Value | $104M | $75M | $226M | $41M | $69M | $232M | $152M | $19M | $34M | $117M | $103M |
| P/E Ratio → | -1.63 | — | — | — | 11.30 | — | — | — | — | — | — |
| P/S Ratio | 77.34 | 66.95 | 10.90 | 4.11 | 1.24 | 3.65 | 15.40 | 13.53 | 54.96 | 806.64 | 18.55 |
| P/B Ratio | — | — | — | — | 1.46 | 13.79 | — | 10.76 | — | 3.22 | 2.73 |
| P/FCF | — | — | — | — | — | — | 7.50 | — | — | — | — |
| P/OCF | — | — | — | — | — | — | 7.33 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RNAC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 26.74 | 5.80 | 1.58 | 0.62 | 2.72 | 9.17 | 2.91 | 37.22 | 566.76 | 12.79 |
| EV / EBITDA | — | — | — | — | 4.15 | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 1.82 | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 4.47 | — | — | — | — |
RNAC Profitability
Margins and return-on-capital ratios measuring operating efficiency
Cartesian Therapeutics, Inc. earns an operating margin of -3099.9%. Operating margins have compressed from -332.3% to -3099.9% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 98.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -3099.9% | -3099.9% | -112.8% | -332.3% | 13.1% | -5.4% | -342.4% | -785.6% | -7200.7% | -30813.5% | -428.9% |
| Net Profit Margin | -4658.6% | -4658.6% | -199.0% | -844.9% | 31.9% | -30.2% | -415.0% | -829.0% | -7235.4% | -31556.0% | -448.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | 60.8% | -1137.9% | — | -3716.0% | -281.6% | -122.4% | -65.9% |
| ROA | -35.6% | -35.6% | -20.9% | -93.3% | 21.7% | -15.8% | -52.0% | -76.8% | -89.8% | -68.6% | -54.8% |
| ROIC | — | — | — | — | 43.1% | — | — | — | — | -910.9% | — |
| ROCE | -25.0% | -25.0% | -13.5% | -45.8% | 12.7% | -5.4% | -76.5% | -141.8% | -130.7% | -77.0% | -62.4% |
RNAC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $125M exceeds total debt of $13M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.40 | 1.57 | — | 2.30 | — | 0.41 | 0.22 |
| Debt / EBITDA | — | — | — | — | 2.29 | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -0.73 | -3.50 | — | -8.44 | — | -0.96 | -0.85 |
| Net Debt / EBITDA | — | — | — | — | -4.13 | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -3.03 | — | — | — | — |
| Interest Coverage | — | — | — | -83.26 | 12.47 | -2.42 | -43.26 | -35.44 | -42.73 | -53.16 | -27.90 |
Net cash position: cash ($125M) exceeds total debt ($13M)
RNAC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Cartesian Therapeutics, Inc.'s current ratio of 8.65x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.33x to 8.65x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.65 | 8.65 | 9.43 | 1.33 | 5.91 | 2.00 | 1.86 | 2.77 | 1.20 | 8.99 | 6.33 |
| Quick Ratio | 8.65 | 8.65 | 9.43 | 1.33 | 5.91 | 2.00 | 1.86 | 2.77 | 1.20 | 9.18 | 6.33 |
| Cash Ratio | 8.38 | 8.38 | 9.25 | 1.13 | 5.37 | 1.77 | 1.70 | 2.58 | 1.06 | 8.81 | 6.14 |
| Asset Turnover | — | 0.01 | 0.09 | 0.09 | 0.67 | 0.53 | 0.10 | 0.07 | 0.02 | 0.00 | 0.09 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 145.50 | 8.18 | 124.24 | 32.48 | 42.53 | 158.87 | 273.33 | — | 111.09 | 9.71 |
RNAC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cartesian Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 8.8% | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 13.3% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 5.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 5.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $26M | $24M | $5M | $4M | $3M | $3M | $1M | $621924 | $567362 | $291497 |
Peer Comparison
Compare RNAC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RNACYou | $216M | -1.6 | — | — | 100.0% | -3099.9% | — | — | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 LEGN | $5B | -8.9 | — | — | 60.3% | -13.3% | -29.1% | -12.7% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See RNAC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNAC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RNAC vs KYMR
Side-by-side business, growth, and profitability comparison vs Kymera Therapeutics, Inc..
Start ComparisonRNAC — Frequently Asked Questions
Quick answers to the most common questions about buying RNAC stock.
What is Cartesian Therapeutics, Inc.'s P/E ratio?
Cartesian Therapeutics, Inc.'s current P/E ratio is -1.6x. The historical average is 11.3x.
Is RNAC stock overvalued?
Based on historical data, Cartesian Therapeutics, Inc. is trading at a P/E of -1.6x. Compare with industry peers and growth rates for a complete picture.
What are Cartesian Therapeutics, Inc.'s profit margins?
Cartesian Therapeutics, Inc. has 100.0% gross margin and -3099.9% operating margin.